Company: DMAC
Filing Date: 2025-08-12
Form Type: S-3
Source: 0001437749-25-026273
Chunk: 52

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: S-3
Chunk 52
---
 590,000 common shares reserved for issuance upon the exercise of outstanding stock options under the DiaMedica Therapeutics Inc. 2021 Employment Inducement Plan (2021 Plan), with a weighted average exercise price of $2.53 per share; |

| ● | 754,919 common shares reserved for future issuance in connection with future grants under the 2019 Plan; and |

| ● | 357,500 common shares reserved for future issuance in connection with future grants under the 2021 Plan. |

The number of our common shares to be outstanding after this offering also excludes 8,606,425 shares issued and 1,000,000 common shares reserved for future issuance in connection with future grants under the 2021 Plan subsequent to June 30, 2025 through August 12, 2025.

<div align='center'>S-14

PLAN OF DISTRIBUTION</div>

We have entered into a Sales Agreement with TD Cowen, under which we may issue and sell from time to time up to $100,000,000 of our common shares through or to TD Cowen as our sales agent or principal. Sales of our common shares, if any, will be made in negotiated transactions, including block trades or block sales, or by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act, including without limitation sales made through Nasdaq or on any other existing trading market for our common shares, or by any other method permitted by law. Sales pursuant to the Sales Agreement may be made through an affiliate of TD Cowen. No common shares will be offered or sold pursuant to the Sales Agreement in Canada, to anyone known to be a resident of Canada or on or through the facilities of any exchange or trading market in Canada, and there will be no solicitations or advertising activities undertaken in Canada in connection with this offering.

TD Cowen will offer our common shares subject to the terms and conditions of the Sales Agreement on a daily basis or as otherwise agreed upon by us and TD Cowen. We will designate the maximum amount of common shares to be sold through TD Cowen on a daily basis or otherwise determine such maximum amount together with TD Cowen. Subject to the terms and conditions of the Sales Agreement, TD Cowen will use its commercially reasonable efforts to sell on our behalf all of the common shares requested to be sold by us. We may instruct TD Cowen not to sell common shares if the sales cannot be effected at or